摘要
目的:观察蒙药德都红花-7味散对非酒精性脂肪肝的治疗作用及其机制,为临床用药提供理论依据.方法:取Wister♂大鼠,随机分为空白组8只、空白给药(德都红花-7味散)、模型组、德都红花-7味散低、高剂量组,各组10只.除空白组和空白给药组,按2 m L/100 g脂肪乳剂灌胃,1次/d,共计给脂肪乳剂灌胃4 wk.空白给药组、德都红花-7味散低、高剂量组分别给予蒙药德都红花-7味散0.6、0.6、3.0 g/(kg·d).各给药组均提前7 d给药,给药体积为1 m L/100 g,1次/d,灌胃给药;其他两组灌胃等体积蒸馏水,共计给药5 wk.观察各组大鼠血脂四项,肝功,肝组织匀浆中总胆固醇(cholesterol,CHO)、甘油三酯(triglyceride,TG)、超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)含量;HE染色观察肝脏细胞脂肪变程度.结果:与空白组比较,模型组大鼠血清TG、CHO、低密度脂蛋白(low density lipoprotein cholesterol,LDL-C)、肝匀浆TG、CHO、MDA、空白给药组MDA升高,血清高密度脂蛋白(high density lipoprotein cholesterol,HDL-C)、肝匀浆SOD明显降低;德都红花-7味散低、高剂量组大鼠血清CHO、LDL-C升高,有显著性差异(P<0.05).与模型组比较,低剂量组血清TG降低,高剂量组血清CHO、LDL-C降低、HDL-C升高,空白给药组肝匀浆TG、CHO、MDA降低,SOD升高;低剂量组肝匀浆TG、CHO、MDA降低,高剂量组肝匀浆TG、MDA降低,SOD升高有显著性差异(P<0.05).给药组肝组织脂肪变程度较模型组明显减轻.结论:蒙药德都红花-7味散治疗高质饮食脂肪肝疗效确切,抗脂质过氧化可能是其治疗机制的一部分.
AIM：To observe the therapeutic effect of traditional Mongolian medicine Deduhonghua-7 powder on non-alcoholic fatty liver disease and to explore the underlying mechanism.METHODS：Male Wistar rats were randomly divided into a normal control group,a blank medication group,a model group,and low- and high-dose Deduhonghua-7powder groups,with 10 rats in each group.Except for the normal control group and blank medication group,the other groups were administered intragastrically with lipid emulsion at 2 mL/100 g once a day for 4 weeks.The blank medication group and low- and high-dose Deduhonghua-7powder groups were intragastrically given0.6,0.6 and 3.0 g/（kg·d） Deduhonghua-7powder（1 mL/100 g） once daily for 5 weeks,respectively,and the other two groups were treated with distilled water for the same duration.Blood lipids,liver function indexes,as well as cholesterol（CHO）,triglyceride（TG）,superoxide dismutase（SOD）,and malondialdehyde（MDA） contents in liver tissue homogenates were measured,and fatty degeneration of liver cells was observed by HE staining.RESULTS：Compared with the blank control group,serum TG,CHO,and low density lipoprotein cholesterol（LDL-C）,as well as TG,CHO,and MDA in liver tissue homogenates in the model group and MDA in the blank medication group were increased,and high density lipoprotein cholesterol（HDL-C） and hepatic SOD were decreased;CHO and LDL-C were significantly increased in the Deduhonghua-7 powder groups（P〈 0.05）.Compared with the model group,serum TG in the low-dose group,and CHO and LDL-C in the high-dose group were significantly decreased,and HDL-C was significantly increased;TG,CHO,and MDA in liver tissue homogenates in the blank medication group were significantly decreased,and SOD was significantly increased;TG,CHO,and MDA in liver tissue homogenates in the low-dose group,and TG and MDA in the high-dose group were significantly decreased,and SOD was significantly increased（P〈 0.05 for all）.Compared with the model group,the fatty degeneration of liver cells was alleviated in the medication groups.CONCLUSION：Deduhonghua-7 powder can regulate the lipid metabolism to improve lipid peroxide and show a therapeutic effect on nonalcoholic fatty liver.
出处
《世界华人消化杂志》
CAS
2015年第31期5011-5016,共6页
World Chinese Journal of Digestology
基金
内蒙古自治区科技计划项目
No.20130413~~
